ProCE Banner Activity

Frequently Asked Questions on PAH

Clinical Thought
What is the role of generics, inhaled prostacyclins, and oxygen?

Released: March 30, 2021

Expiration: March 29, 2022

Share

Faculty

James Christensen

James Christensen, PhD

Director
Translational Research, Oncology
Pfizer Global Research and Development
La Jolla, California

Martha Kingman

Martha Kingman, DNP, FNP-C

Nurse Practitioner
Pulmonary Hypertension Program
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas

Vallerie V. McLaughlin

Vallerie V. McLaughlin, MD

Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine
Interim Chief Clinical Officer, Ambulatory Care Services
Director, Pulmonary Hypertension Program
Michigan Medicine
Ann Arbor, Michigan

Provided by

Provided by ProCE, LLC
ProCE Banner

Supporters

Actelion Pharmaceuticals a Janssen Pharm JJ

Faculty Disclosure

Primary Author

James Christensen, PhD

Director
Translational Research, Oncology
Pfizer Global Research and Development
La Jolla, California

James C. Coons, PharmD, FCCP, BCCP, has conducted contracted research for Pfizer and United Therapeutics; received consulting fees from Alnylam and Bristol Myers Squibb.

Martha Kingman, DNP, FNP-C

Nurse Practitioner
Pulmonary Hypertension Program
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas

Martha Kingman, DNP, FNP-C, has conducted contracted research for and received consulting fees from Acceleron, Actelion, and United Therapeutics; received consulting fees from Altavant, Caremark, CiVi Biopharma, Gossamer Bio, and Liquidia; conducted contracted research for Reata and Sonavie.

Vallerie V. McLaughlin, MD

Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine
Interim Chief Clinical Officer, Ambulatory Care Services
Director, Pulmonary Hypertension Program
Michigan Medicine
Ann Arbor, Michigan

Vallerie McLaughlin, MD, has received consulting fees from Actelion/J&J, Bayer, and United Therapeutics.